Comparison Between Two Strategies of Discharge Planning for the Reduction of Short Term Hospital Readmissions

Overview

The purpose of this study is to improve discharge planning effectiveness by comparing two strategies [on-Demand Discharge Planning (DDP) vs. Routine Discharge Planning (RDP)], in terms of reduction of hospital readmissions for inpatients classified at intermediate risk of complex discharge using the simplified Blaylock Risk Assessment Screening Score (BRASS).

Full Title of Study: “Comparison Between Two Strategies of Discharge Planning for the Reduction of Short Term Hospital Readmissions: A Cluster Randomized Cross-over Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Other
    • Masking: None (Open Label)
  • Study Primary Completion Date: October 12, 2019

Detailed Description

The purpose of this study is to improve discharge planning effectiveness by comparing two strategies [on-Demand Discharge Planning (DDP) vs. Routine Discharge Planning (RDP)], in terms of reduction of hospital readmissions for inpatients classified at intermediate risk of complex discharge using the simplified Blaylock Risk Assessment Screening Score (BRASS). Five Internal Medicine Unit and four Units of Neurology will be randomized to the two different strategies of discharge planning (RDP or DDP), based on two different alternating sequences of four periods (each period comprising three months). The randomization will be stratified by type of unit. Patients at risk of complex discharge, according to the simplified BRASS score, are assigned to the Hospital Unit of Continuity of Care (NOCC) team, using the hospital telematics system. Afterwards, the NOCC team proposes an appropriate discharge planning, considering clinical and social needs.

Interventions

  • Other: On Demand Discharge Planning (DDP)
    • Patients with an intermediate score, according to the simplified Blaylock Risk Assessment Screening Score, are addressed to the NOCC team (hospital Continuity of care team) only in case of a specific request by the unit of hospitalization.
  • Other: Routine Discharge Planning (RDP)
    • All patients with an intermediate threshold value of the simplified Blaylock Risk Assessment Screening Score are submitted to discharge planning by the NOCC team (Hospital Unit of Continuity of Care)

Arms, Groups and Cohorts

  • Active Comparator: On Demand Discharge Planning (DDP)
    • Patients with an intermediate score, according to the simplified Blaylock Risk Assessment Screening Score, are addressed to the NOCC team only in case of a specific request by the unit of hospitalization.
  • Experimental: Routine Discharge Planning (RDP)
    • All patients with an intermediate threshold value of the simplified Blaylock Risk Assessment Screening Score are submitted to discharge planning by the NOCC team (Hospital Unit of Continuity of Care)

Clinical Trial Outcome Measures

Primary Measures

  • Unexpected hospital readmission within 90 days from discharge
    • Time Frame: 90 days
    • Proportion of hospital admissions in the standard admission regime within 90 days from the date of discharge. The endpoint will be calculated only for patients discharged alive. Readmissions for any cause under ordinary admissions will be considered as event. The Day Hospital re-admissions will not be considered for the endpoint calculation.

Secondary Measures

  • Proportion of Long Length of Stay (LLOS)
    • Time Frame: 150 days
    • Proportion of admissions with long duration of hospitalization (LLOS – Long Length of Stay). The endpoint will be calculated for all hospitalized patients. An admission will be considered as LLOS if its duration will be higher than the 90th specific percentile for Diagnostic Related Group (DRG ) detected at the regional level in Piedmont in 2016.
  • Death within 90 days from discharge
    • Time Frame: 90 days
    • Proportion of deaths within 90 days of discharge date. The endpoint will be calculated only for patients discharged alive. Death for any cause will be considered as event.
  • Proportion of patients reported to the NOCC team during the DDP-experimental phase
    • Time Frame: 150 days
    • Incidence of activations of the NOCC in the periods of adoption of the DDP strategy (only for admissions treated with DDP strategy)
  • Healthcare costs until 90 days from the discharge
    • Time Frame: 90 days
    • Health care costs charged to the National Health Service (NHS) between the date of admission and 90 days from the date of discharge or death of the patient.

Participating in This Clinical Trial

Inclusion Criteria

  • Adults patients (age ≥ 18 years); – Residents in Piedmont, Italy; – Patients admitted to General Internal Medicine or Neurology Units of Molinette Hospital (Turin) – Patients with a score in the simplified BRASS between 4 and 6 at admission No specific exclusion criteria were applied.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Azienda Ospedaliera Città della Salute e della Scienza di Torino
  • Provider of Information About this Clinical Study
    • Principal Investigator: Daniela Corsi, MD, Director of “SSD Integrazione Ospedale-Territorio” – Azienda Ospedaliera Città della Salute e della Scienza di Torino
  • Overall Official(s)
    • Daniela Corsi, MD, Principal Investigator, Azienda Ospedaliera Città della Salute e della Scienza di Torino

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.